Primary Hyperoxaluria (Types 1-3) Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

Germany

High-Risk Population

Children and young adults with recurrent calcium oxalate stones, nephrocalcinosis, unexplained chronic kidney disease, or kidney failure are high-risk groups. Individuals from populations with higher frequencies of specific pathogenic variants and families with consanguinity also warrant particular attention.

Key Diagnostic Method

Diagnosis combines urinary oxalate measurement, plasma oxalate in advanced kidney disease, stone composition, renal imaging, biochemical testing, and molecular analysis of AGXT, GRHPR, and HOGA1. Genetic testing is increasingly central because biochemical phenotypes overlap and early diagnosis can alter management.

Major Risk Factor

The fundamental risk factor is biallelic pathogenic variation in AGXT, GRHPR, or HOGA1. Consanguinity, family history, recurrent nephrolithiasis, nephrocalcinosis, and unexplained kidney failure increase the clinical suspicion for inherited PH.

Major gap in the market

Major gaps include prolonged diagnostic delay, under-recognition of PH2 and PH3, limited access to genetic testing, insufficient screening of recurrent stone formers, limited subtype-specific biomarkers, high treatment burden, and restricted availability of disease-modifying therapy outside PH1.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Clinically diagnosed PH has traditionally been estimated at approximately 1–3 per million population. A 2025 genetic analysis produced substantially higher estimates based on pathogenic/likely pathogenic variants: approximately 4.8 per million for PH1, 1.2 per million for PH2, and 11.0 per million for PH3. The authors estimated an overall genetic risk of approximately 1 in 59,017.

Gender-Specific Cases of the Disease

PH is inherited in an autosomal-recessive manner and therefore affects both sexes. Recent Japanese PH1 data identified 12 females and 7 males among 20 patients with known sex, although this small literature-derived cohort cannot establish a population-level sex difference. The 2024 French nationwide cohort also demonstrated disease across both pediatric and adult populations.

Age-Specific Cases of the Disease

PH can present from infancy to adulthood. In a 2024 French nationwide cohort of 52 genetically diagnosed patients, 34 were children and 18 were adults. Median diagnostic delay was 1.2 years in children versus 30 years in adults. In Japan, the 2026 PH1 review reported median symptom onset at 4.21 years and median diagnosis at 5.5 years.

Ethnicity-Wise Cases of the Disease

Genetic prevalence varies considerably between populations. The 2025 global analysis estimated the highest AGXT pathogenic-variant carrier frequency in East Asians at approximately 1 in 146 and in European non-Finnish populations at 1 in 187. GRHPR carrier frequency was highest in South Asians at approximately 1 in 313, while HOGA1 carrier frequency was particularly high among Ashkenazi Jewish populations at approximately 1 in 38.

Mortality and Survival Analysis of the Disease

PH1 carries the greatest risk of progressive kidney failure and systemic oxalosis. In a 2023 Chinese PH1 literature review, 51.1% of patients had reached end-stage renal disease and 38.9% had died. A 2026 Japanese PH1 review reported an overall survival rate of 81% at 5, 10, and 20 years after diagnosis, although the cohort was small and literature-derived.

Disease Type

Prevalence

Primary Hyperoxaluria Type 1 (PH1)

PH1 is caused by pathogenic variants in AGXT and is the most clinically severe and frequently diagnosed PH subtype. A 2025 genetic analysis estimated PH1 prevalence at approximately 1 in 209,357 individuals, or nearly 5 per million. Disease commonly presents with recurrent calcium oxalate stones, nephrocalcinosis, progressive kidney impairment, and systemic oxalosis.

Primary Hyperoxaluria Type 2 (PH2)

PH2 results from biallelic GRHPR variants and generally demonstrates a more heterogeneous and less severe renal course than PH1. The 2025 genetic analysis estimated prevalence at approximately 1 in 863,028, or about 1.2 per million. Its lower clinical recognition relative to genetic estimates suggests substantial underdiagnosis, particularly among patients with recurrent calcium oxalate stones.

Primary Hyperoxaluria Type 3 (PH3)

PH3 is caused by pathogenic HOGA1 variants and has emerged as the genetically most prevalent PH subtype in contemporary genomic analysis. The 2025 study estimated prevalence at approximately 1 in 90,834, or nearly 11 per million. PH3 frequently presents with childhood nephrolithiasis but generally demonstrates slower renal decline than PH1, contributing to substantial underdiagnosis.

Country

Key Insights

United States

The United States has major PH expertise through inherited kidney-disease and rare-stone networks. Contemporary management increasingly incorporates genetic diagnosis and RNA-interference therapy for PH1. Population-level diagnosed prevalence remains difficult to establish because many patients are identified only after recurrent stones, nephrocalcinosis, or chronic kidney disease.

Germany

Germany contributes to European PH research and rare metabolic kidney-disease care. Contemporary European practice emphasizes molecular confirmation and early identification of patients with recurrent calcium oxalate stones or unexplained nephrocalcinosis. National population-based prevalence data meeting the 2023–2026 evidence requirement remain limited.

France

France has particularly strong contemporary epidemiological evidence. A 2024 nationwide cohort included 52 genetically diagnosed patients, comprising 40 PH1, 3 PH2, and 9 PH3. At diagnosis, 23% required dialysis, while 13% underwent double liver-kidney transplantation and 13% isolated kidney transplantation. A 2026 French follow-up cohort of 62 patients reported 42 PH1, 5 PH2, and 11 PH3 cases and found that diagnostic delay had approximately halved compared with the earlier cohort.

Italy

Italy contributed to the 2025 global genetic-prevalence analysis through investigators from the University of Torino and represents an important European centre for PH genetics. The contemporary analysis estimated global PH1, PH2, and PH3 genetic prevalence at approximately 5, 1, and 11 per million, respectively. Italian population-specific clinical prevalence remains insufficiently established.

Spain

Spain participates in European rare kidney disease and urolithiasis research, although a contemporary nationwide PH prevalence estimate is not well established. Current European diagnostic approaches emphasize molecular confirmation in patients with recurrent calcium oxalate stones, nephrocalcinosis, early kidney failure, or a family history compatible with inherited hyperoxaluria.

United Kingdom

The United Kingdom has longstanding expertise in PH genetics and metabolic stone disease. UK researchers contributed to the 2025 global genetic-prevalence analysis, which highlighted substantial underdiagnosis of PH2 and PH3. Current UK clinical practice increasingly incorporates molecular diagnosis and specialist inherited-stone pathways, but national 2023-2026 clinical prevalence remains incompletely quantified.

Japan

A 2026 review of Japanese PH1 cases reported 20 patients diagnosed between 2003 and 2023, including 7 males and 12 females, with one patient of unspecified sex. Median symptom onset was 4.21 years and median diagnosis was 5.5 years. Half were diagnosed before age 18, while 44% of those pediatric patients had already reached kidney failure.

India

India has substantial clinical relevance because South Asian populations show a relatively high estimated GRHPR carrier frequency. The 2025 global genetic analysis estimated the GRHPR pathogenic-variant carrier frequency in South Asians at approximately 1 in 313. Contemporary Indian reports also demonstrate that PH2 may present as unexplained advanced kidney disease in adolescents, reinforcing the need for genetic evaluation.